MOLOGEN AG

  • WKN: A2LQ90
  • ISIN: DE000A2LQ900
  • Land: Deutschland

Nachricht vom 22.07.2019 | 09:25

MOLOGEN AG: Publication of important results from the TEACH study in HIV patients

DGAP-News: MOLOGEN AG / Key word(s): Study/Study results

22.07.2019 / 09:25
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE N 12 / 2019 of 07/22/2019

MOLOGEN AG: Publication of important results from the TEACH study in HIV patients

Berlin, 22 July 2019 - The biopharmaceutical company MOLOGEN AG (ISIN DE000A2LQ900, SIN A2L Q90) reports today that the renowned scientific journal EBioMedicine (Journal of The Lancet group) published a comprehensive article on the exploratory phase Ib/IIa TEACH trial using the company's lead compound, lefitolimod, in the HIV indication. The study, conducted in cooperation with the Aarhus University Denmark and which concluded in 2018, showed important positive effects of lefitolimod on the activation of anti-viral immunity in HIV patients treated with anti-retroviral therapy (ART). The publication presents further important findings regarding the ability of lefitolimod to modulate the immune response in the lymph nodes of HIV patients by inducing the differentiation of B cells and promoting a marked interferon response. This modulation of anti-viral immunity in the lymph nodes by lefitolimod is especially important given that this is where HIV persists, and thus evades antiretroviral therapy. These data, combined with the favorable safety profile of lefitolimod which was again confirmed, are another important stepping stone in the development strategy for lefitolimod in HIV.

Lefitolimod is an immune-therapeutic drug candidate, consisting of entirely natural DNA, which is in late-stage clinical development, currently being investigated in the pivotal phase III IMPALA study in the metastatic colorectal cancer indication, of which top-line results are expected in August 2019, as well as in a phase IIa combination study with the Yervoy(R) (Ipilimumab) in various solid tumors.

In HIV, the phase IIa TITAN study, which is financed by pharmaceutical drug company Gilead Sciences Inc., Foster City, USA, is expected to start recruiting in summer 2019. Moreover, plans for another combination study with a renowned U.S. center are at an advanced stage.

MOLOGEN's product pipeline also includes the next generation platform EnanDIM(R). The preclinical development of a first candidate from that family of TLR9 agonists progressed as planned and the start of the clinical phase is expected for the end of 2019.

The full publication in EBioMedicine is available at: https://doi.org/10.1016/j.ebiom.2019.07.005

MOLOGEN AG
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.

The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM(R).

The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published.
In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.

MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com


Contact
Claudia Nickolaus

Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 37
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com


Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

 



22.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

HanseYachts: „Der ideale Zeitpunkt für den Kauf“

Die Übernahme des Katamaran-Herstellers Privilège bringt die HanseYachts AG dem Umsatzziel von 200 Mio. Euro einen bedeutenden Schritt näher. „Der Katamaran-Markt ist das derzeit am stärksten wachsende Segment im Yacht-Geschäft. Privilège ist weltweit in Preis und Qualität die Nummer eins“, so CEO Dr. Jens Gerhardt. Zudem sei der Deal ein wichtiger Faktor, um die EBITDA-Marge auf 10 bis 12 % zu steigern. Im Financial.de-Interview spricht der Konzernlenker über die aktuellsten Trends im Yacht-Geschäft, die laufende Barkapitalerhöhung sowie die Weltpremieren in Cannes.

GBC-Fokusbox

Fonds Research 2019: S.E.A. Asian High Yield Bond bietet attraktive Investitionschance

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter auch den S.E.A. Asian High Yield Bond (ISIN: LU1138637738), der eine gute Anlagechance anbietet mit einer Strategie, die kaum reproduzierbar ist. Insbesondere vor dem Hintergrund des anhaltenden Niedrigzinsniveaus sehen wir den Anleihefonds als äußerst attraktive Investitionschance, um nachhaltige und volatilitätsarme Renditen zu erzielen. Wir haben den S.E.A. Asian High Yield Bond mit 4 von 5 Falken eingestuft.

Aktueller Webcast

EQS Group AG

Conference Call zu den Halbjahreszahlen 2019

16. August 2019

Aktuelle Research-Studie

Tick Trading Software AG

Original-Research: tick Trading Software AG (von GBC AG): Kaufen

22. August 2019